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esponsibility of InstAbstract The pharmaceutical industry is presently suffering difﬁcult times due to low productivity
of new molecular entities. As a major source of drug leads, high-throughput screening (HTS) has
been often criticized for its ‘dead end’ lead compounds. However, the fruitful achievements resulting
from HTS technology indicate that it remains a feasible way for drug innovation. Because of
increasing considerations of earlier stage ADMET (absorption, distribution, metabolism, excretion
and toxicity) in drug development, cell-based HTS is highly recommended in modern drug discovery
for its ability to detect more biologically relevant characteristics of compounds in living systems. This
review provides a systematic and practical description of vital points for conducting high quality cell-
based HTS, from assay development to optimization, compound management, data analyses, hit
validation as well as lead identiﬁcation. Potential problems and solutions are also covered.
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High-throughput screening (HTS), driven by the great pro-
gress in automation technology and combinatorial chemistry,
has been widely implemented in drug discovery since the early
1990s and rapidly became one of the major sources of drug
leads. Pharmaceutical companies, such as Pﬁzer and Glaxo
SmithKline, were among the early leaders. In the past twenty
years or so, many academic institutions joined the ‘screening
mania’ and simultaneously, hundreds of screening centers
appeared, as molecules available for screening continued to
increase. However, in spite of constant increases in research
and development (R&D) expenditures, the number of new
chemical entities (NCEs) that reached to the market has
actually decreased1,2. Analyses show that leads originating
from HTS are responsible for over 60% of clinical trial
failures3,4. Nonetheless, the data also indicate that among 58
drugs that were approved between 1991 and 2008, 19 were
attributed to HTS5. Without question, HTS is still a feasible
approach to drug innovation. The problem becomes one of
how to improve the quality of leads arising from drug
screening that may result in increased productivity of new
molecular entity (NME) entering to the market place.
Since HTS has not substantially improved the drug discovery
process and increased R&D spending has not led to a propor-
tionate increase in new drug output, the pharmaceutical
industry is looking back to the golden age of phenotype-
oriented drug discovery6 and considering ADMET (absorption,
distribution, metabolism, excretion and toxicity) of leads at
earlier stages in drug development. A potential way to do this is
through the use of cell-based assays. Cell-based assays not only
obtain potencies of compounds but also detect cytotoxicity,
permeability and effects on growth at the same time, which can
be viewed as predictors for late development. Cell-based assays
accounted for 52.6% of all HTS efforts in 20067 and became
more favorable in recent years. However, cell-based assays are
generally more complicated than biochemical ones and their
performance could be undesirable under certain circumstances.
Thus, quality control is of paramount importance and will be
discussed in detail below. Although several comprehensive
reviews are accessible in the public domain, this article attempts
to give key points relevant to carrying out high quality cell-
based HTS in a systematic and practical manner with potential
problems and solutions highlighted.
Basically, HTS program consists of ﬁve parts: target
identiﬁcation, reagent preparation, assay development, com-
pound management and high-throughput screening8. Among
them, target identiﬁcation and reagent preparation are beyond
the interest of this review, although both of them are vital for
successful HTS. Instead, we will cover topics such as assay
development and optimization, compound management and
data analysis, as well as hit identiﬁcation and lead validation.
High content screening (HCS), as an important part of cell-
based HTS, has attracted signiﬁcant attention recently because
of its multiplexing and functional cell based characteristics9.
However, considering the complexity of its data analysis, HCS
is not included in this discussion.
2. Assay development
Cell-based assays or screening models, as the fundamental
ingredient of HTS, are approaches used for sensing functionalchanges of targets under the stimulatory or inhibitory effects of
compounds. In biochemical assays, targets are generally
speciﬁed, while for cell-based assays, the exact target is not
required. It could be a speciﬁc molecule or a particular
signaling pathway, even the whole cell. For example, in cell
death assays10, organisms such as bacteria, fungi, parasites and
mammalian cells are directly used as screening models. These
whole cell based screenings are highly physiologically relevant,
thus providing opportunities to discover entirely novel drugs
and drug targets. However, subsequent pharmacological char-
acterization and target identiﬁcation could be exhaustive. Most
of the time, speciﬁc targets are decided as soon as screening
assays are proposed.
Cell lines used for HTS can be roughly divided into two
classes, primary and engineered cells. With technology advance-
ments, such as HCS, ion channel patch-clamp and atomic force
microscopy, screenings with primary cells become increasingly
feasible and trendy11. Several selected primary cell types, originat-
ing from human or other species, are commercially available (e.g.,
Clonetics, Walkersville, MD, USA) and amenable to HTS. As far
as mammalian cell based assays are concerned, large-scale
primary cell culture still poses some difﬁculties. Therefore,
engineered cells remain the major type of cell lines used in
HTS. In the following discussion, we offer some general ideas and
tips for generation of engineered cell lines and related detection
methods.2.1. Cell line generation
To provide sufﬁcient signal output for detection, cell-based
assays require high expression of targeted proteins, which in
naive cells is often low and needs to be up-regulated through
either transient or stable gene transfection12. The transient
transformed cell lines brieﬂy express high level of targeted
proteins, but display relatively larger variances in expression
quality due to transfection inefﬁciencies. Stable transformed
cell lines consistently express targeted proteins over a long
period of time, while their expression levels are usually not as
high as transient ones. Both strategies can be employed in
HTS13, but stable expression is much more preferred because
of reduced cost and less assay variation14.
Generally, gene transfection requires primary knowledge
about the sequence of a targeted protein for vector construc-
tion. It is noted that some genes of interest are protected by
patents that prohibit commercial use. Alternative strategies
must be sought under such a situation: one can either increase
the expression level of a particular gene through activation of
internal gene scripts15,16 or introduce speciﬁc transcriptional
factors17. Sometimes, simply increasing the expression of a
targeted gene is not sufﬁcient to yield a high signal output and
genes involved in the same signaling pathway may also need to
be enhanced. For instance, G protein enriched cell lines, such
as Ga16 or Gqi5 transfected CHO cells, are preferred to
screening G protein coupled receptor (GPCR) modulators.2.2. Detection methods
A variety of methods, such as reporter gene, ﬂuorescence/
bioluminescence resonance energy transfer (F/BRET), calcium
mobilization and label-free detection, have been applied to
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approaches to the screening of small molecular modulators.
2.2.1. Reporter gene assay
Many receptors, kinases and transcriptional factors regulate
gene expression either directly or indirectly through signal
transduction. By accessing these signal cascades, reporter gene
technique offers great sensitivity for signal detection in cell-
based assays. As we know, the sensitivity and efﬁciency of
reporter gene systems are largely affected by both reporter gene
and promoter upstream. In order to guarantee wide detecting
windows and high resolutions, promoters with very low
constitutive activities should be sought. This will ensure an
optimal background and signiﬁcant response in the presence of
a stimulus. For reporter gene products, an appropriate level of
stability is also vital. Long half-time may lead to an increased
background resulting from excess accumulation of reporter
gene encoded proteins. This could be caused by constitutive
activation of promoters or lagging response to stimulations.
Clearly, rational selection of both promoter and reporter gene
according to the purpose and requirement of an assay is an
indispensable step before HTS. Reporter genes that are
commonly utilized today include green ﬂuorescent protein
(GFP), b-galactosidase, ﬁreﬂy luciferase, Renila luciferase
and b-lactamase. The most widely used bioluminescent repor-
ter genes are ﬁreﬂy luciferase from Photinuspyralis and Renilla
luciferase derived from the sea pansy Renillareniformis. These
bioluminescent reporter assays are of both high sensitivity and
extraordinary accuracy. Because the readout is determined by
efﬁciency of signal transduction and cellular physical/metabolic
integrity, however, the false positive rate can be high18. Efforts
in follow-up hit veriﬁcation with secondary assays are generally
required as a routine.
2.2.2. cAMP measurement
cAMP is one of the most important second messengers involved
in a variety of physiological responses and is thus widely
measured in HTS. Present methods for cAMP measurement
include ﬂuorescence polarization (FP)19, HitHunter EFC tech-
nology based on b-galactosidase activity complementation,
cyclic-nucleotide-gated ion channel (CNGC) coupled cAMP
assay based on membrane potential20, as well as cAMP-Glo
assay developed by Promega. All of them reﬂect a decline of
ﬂuorescent signals in response to an increase in cAMP concen-
tration. Other cAMP assays, based on reporter gene by splicing
the reporter luciferase coding sequence under the control of Cre
(causes recombination), measure elevations of cAMP levels
exhibited as an increase in ﬂuorescence/luminescence intensity.
Obviously, this approach is labor intensive (requires more than
4 hours) and reﬂects cAMP concentration indirectly. Although
cAMP measurements tend to offer more accurate and physio-
logically relevant results with low false positive hits, some of
them require special apparatus/ﬁttings (e.g., optical ﬁlters) and
expensive regents (e.g., engineered antibodies fused with com-
pensatory enzyme or ﬂuorescent indicators).
2.2.3. FRET and BRET techniques
Protein–protein interaction is one of the key problems in
mechanistic studies of critical cellular processes and diseases.
Fluorescence resonance energy transfer (FRET) and biolumi-
nescence resonance energy transfer (BRET) are among a rangeof available methods for studies on such interaction. In brief,
the resonance energy transfer refers to energy transfer between
ﬂuorescent/luminescent donor and acceptor molecules when
they are in close proximity (1–10 nm) with properly oriented
dipoles. Frequently used donors include blue ﬂuorescent
protein (BFP) and cyan ﬂuorescent protein (CFP) for FRET,
and luminescent products of luciferase for BRET. Commonly
used acceptors include GFP, Venus, Citrine, YPet and mOr-
ange. Efﬁciency of transfer and resolution of detection are
greatly inﬂuenced by spectral properties of both donors and
acceptors, in addition to expression ratio of donor and
acceptor fusion proteins21. Donor–acceptor pairs with compa-
tible spectral properties ensure efﬁcient energy transfer and
high signal to noise ratio. The emission spectrum of a donor
must to some extent overlap the excitation spectrum of the
acceptor to enable high efﬁcient transfer, but a pronounced
overlap would, on the other hand, sacriﬁce detection resolution
resulting in poor signal to noise ratio. Moreover, efﬁciency is
also markedly affected by comparative expression of donor vs.
acceptor fusion proteins, especially when they form homo-
geneous dimmers21. Thus, it is critical to optimize protein
expression pattern before prior to HTS campaign.2.2.4. Calcium mobilization
Cellular Ca2þ is essential to a large number of physiological
processes ranging from embryonic development to muscle
contraction. In silent status, the cytosol Ca2þ is maintained
at a very low level around 100 nM, however, it would burst to
several mM with appropriate stimulation. The calcium inﬂux is
triggered by activation of Ca2þ channels on the plasma
membrane or release of Ca2þ from endoplasmic reticulum.
Today, numerous Ca2þ indicators have been developed for
quantiﬁcation of this important second messenger, involving
protein indicators such as aequorin and chemical indicators
such as Fluo-4. Protein indicators stably expressed in the cell
could signiﬁcantly reduce screening complexity, thereby
increasing throughput compared with chemical indicators
which may need additional steps for dye loading. One draw-
back relates to the extra efforts required for generation of cell
lines that express desired indicators: some of them are now
commercially available (e.g., aequorin). In contrast, chemical
Ca2þ indicators are more conveniently used nowadays due to
their wide range of spectral properties, large detection windows
and robust performance.2.2.5. Label free methods
Although reporter gene and ﬂuorescent/luminescent probe
based assays have been widely deployed in HTS with great
successes, transfection of engineered cells and dye loading
manipulation sometimes cause distortion in cell physiology,
leading to loss of data ﬁdelity and reliability22. The emergence
of innovative label-free platforms aims at overcoming the
limitations of label-based measurements by providing non-
invasive means of detection. This approach enables real-time
trace of kinetic information concerning a signal transduction
process that is inevitably omitted by conventional traditional
end-point assays. Current label-free systems used in cell-based
investigations could be categorized into three major classes
according to different detection principles: quartz micro-
balance, refraction index and cell impedance22–25. Quartz
microbalance and refraction index are frequently employed
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applicable to HTS. Impedance could be used in screening for
potential leads that modulate a variety of biological events
such as cell attachment, apoptosis, migration and activities of
speciﬁc receptors such as GPCRs and tyrosine kinases. For
example, CellKey system and RT-CES are amenable for 96-
and 384-well plate based HTS with a throughput around
20,000 samples per 6 hours. However, signiﬁcant cost asso-
ciated with special assay plates makes these methods less
attractive in large-scale operations.
2.2.6. Membrane potential
Membrane potential can be determined by negatively charged
indicators based on direct optical ﬂuorescence or FRET26. The
efﬁciency and accuracy of such measurement are largely
dependent upon the redistribution of voltage-sensitive indica-
tors: the slower the speed, the less the throughput. Since ion
channels only respond transiently when activated, membrane
potential changes must be promptly recorded. To increase the
throughput one can engineer cells whose fast response chan-
nels are kept open during the redistribution process.
2.2.7. Patch clamp
This technique is the gold standard in monitoring physical
changes of ion channel, while its traditional utility is conﬁned
by low throughput and high manipulation skill. Recently,
remarkable improvements have been made in terms of its
amenability to HTS. Contemporary patch clamp systems are
mostly based on the planar chip recording method, such as
IonWorks Series and PatchXpress 7000 developed by Mole-
cular Devices27,28, Qpatch Series from Sopohion and Patch
linear from Nanion Technologies GmbH. Although these
instruments are adapted to robust HTS, cost per compound
is still considerable that hinders general uses at large. Never-
theless, high quality of biologically relevant data and large
quantities of information generated by patch clamp make it an
attractive tool to be further explored29,30.
2.2.8. Other approaches
In addition to the methods described above, there remain a
variety of approaches applicable to cell-based HTS, such as
ﬂow cytometry, HCS, atomic force microscopy and FP. HCS,
an image analysis oriented technology, is becoming a core
competence in many HTS laboratories because it captures
multiplexing and functional cellular characteristics with
remarkably rapid speed and high efﬁciency. HCS is beyond
the scope of this review due to its complexity. While ﬂow
cytometry is presently capable of screening in small-scale
modulators of cell cycle, apoptosis and proliferation, FP is
widely utilized in protein–protein interaction related HTS.
Clearly, choice of HTS methods depends on the nature of a
target in question. Most commonly used targets include
receptors (GPCRs and nuclear receptors, NRs), ion channels
and enzymes. GPCR assays often involve measurement of
secondary messenger (Ca2þand cAMP) and reporter gene.
Other than these, GPCR modulators can also be screened by
employing the label-free CellKey system developed by Med-
icine Devices. For NRs, speciﬁc ligands can be screened by
ﬂuorescence/luminescence, location-dependant reporter genes
as well as FRET. To assess ion channel activities, membrane
potential, secondary ion messenger (Ca2þ) and patch clamptechniques can be applied27, whereas screening for modulators
of enzymes always relies on their ability to catalyze transfor-
mation of pro-luminescent molecules to luciferase substrates.
The latter can be further converted to bioluminescent mole-
cules readily for luminescence detection (e.g., amino-luciferin
for caspase-3/7 and methyl ester luciferin for monoamine
oxidase). For screening without a speciﬁed target, such as
induced pluripotent stem (iPS) cell stimulators or antibiotics,
image-based methods (HCS and label-free assays) are
preferable.3. HTS optimization
Once an assay has been created, optimization is crucial before
application to large scale screening. Pilot tests are usually
carried out in small scale for a minor batch of known
compounds to determine whether the assay is sufﬁciently
feasible and reliable for HTS. Besides these, a successful
HTS campaign also requires robust performance on a large
scale, under automated and high speed conditions. Parameters
(consistent cell culture, assay miniaturization, microtiter plate
setting, assay automation, etc.) should all be carefully con-
sidered31,32 during scale expansion.
3.1. Cell culture
Cell quality is critical in terms of generating consistent HTS
results. However, sustaining a supply of high quality cells can
always be a challenge, especially when employed cell lines show
poor proliferation. Commonly, cells with the same passage age
are cryo-preserved in large amounts before use, thawed and
cultivated in ﬂasks or plates to desirable conﬂuence when HTS
starts. They are then harvested and seeded into batches of
96/384 microtiter plates for screening. The redundant processes
of cultivation and harvest before seeding may introduce varia-
tions in cell quality over time as well as decrease the speed and
automation of screening. One of the alternative solutions may
be the direct use of cryo-preserved cells. Without secondary
thawing and cultivation, this approach can signiﬁcantly accel-
erate the screening process and increase assay precision33.
Obviously, this will require additional optimization (e.g., selec-
tion of cryo-preservation medium) to make sure that the
recovered cells are fully functional and stable. Another solution
is to utilize division arrested cells. It is known that cells can be
irreversibly division arrested by mitomycin C at a dose that
causes no apparent toxicity or obvious changes to signaling
properties34,35. Division arrested technique allows HTS to be
performed with cells in the same phase, thus increasing the
accuracy of the output. Combination of these methods can
provide a more precise way for running cell-based HTS.
Fortunately, automated cell culture facilities specially developed
for HTS to reduce labor intensity are now commercially
available such as Cell Host system manufactured by Hamilton36.
3.2. Miniaturization
In the early to mid-1990s, most HTS campaigns were carried
out in 96-well microtiter plates. With advances in miniaturiza-
tion and detection technologies, current HTS assays are
usually performed in 384- or 1,536-well plates37. Miniaturiza-
tion increases throughput, improves variation between wells
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40,000 cells per well are usually required to elicit consistent
responses38. When the plate density increases to 1536 wells,
the number of cells in each well decreases to thousands, which
inevitably reduces the resistance to cell diversity resulting in
large variances between wells. In addition, small volume in an
extremely miniaturized assay is more sensitive to environ-
mental changes, such as temperature and humidity, etc. If long
incubation time is required, signiﬁcant edge effects are likely
to appear. Several successful examples of 1,536-well format
HTS were reported in the literature39, but concerns relative to
the quality control of conducting extra large campaigns
remain. It is understandable that the scale of miniaturization
is closely associated with the nature of an assay and the
detection capability of measuring devices. Assays based on
endpoint detection, such as FRET/BRET, reporter gene and
cAMP level, are generally amenable for miniaturization,
whereas methods that measure kinetics, such as calcium
mobilization, label-free impedance and patch clamp, are more
likely preformed in relatively low throughput. Instruments are
now available to allow kinetics based assays to be carried out
in considerable throughput, for instance, the FLIPR system
produced by Molecular Device conducts calcium inﬂux mea-
surement in 384-well format with high precision.
3.3. Plate setting
Currently, both 96- and 384-well plates are commonly used in
cell-based HTS. Since the plates are made for different utilities,
selecting the right one for a particular assay is of great
importance. There are mainly three simple steps in this regard:
(i) plate format and well design; (ii) material and color; and (iii)
surface treatment. Special requirements are developed accord-
ing to assay methods and detection instruments. For example,
solid black polystyrene microplates are designed to reduce well-
to-well cross-talk and background signal for ﬂuorescent assays;
solid white polystyrene plates are produced to decrease well-to-
well cross-talk and background noise thereby enhancing
speciﬁc readouts in luminescent assays. A useful plate selection
guide is available in Corning’s website, which may serve as a
reference for assay development and optimization.
With the right plate, one should decide how to arrange an
assay on it. Apart from testing samples, appropriate controls
must be included in the same plate: positive and negative.
Positive control that exhibits desired response is used to declare
the validity of the assay and serves as a comparison to identiﬁed
hits. Negative control usually produces no response and serves
as the baseline or background, deﬁning compounds with no
activity. Normally, both are needed and set on side columns of
the plate in an alternant and symmetrical way to avoid spatial
variance40,41, while testing samples are arranged inside.
3.4. Automation
It is automation and miniaturization that make HTS possible.
Today, almost every single step of HTS can be automated but
for ordinary screening centers, some of them are optional. The
core of the automated system resides in one or more automatic
multi-channel liquid handling instruments, which are essential
to the production of high quality data. Before setting up a
protocol, thorough understanding of the operation andprecision of the automatic liquid handling system is indis-
pensable. Certain strategies are required for the transfer of
different kinds of liquids in high accuracy. Order of the steps,
speed of dispensing, height of tips, mixing, changing tips and
other related parameters should always be taken into account.
Organization of each step in a proper working ﬂow can
signiﬁcantly increase throughput. For example, dispensing of
a glutinous substance should be slow and the tips should not
be put too deep under the liquid surface to reduce hangover.
Mixing can always improve accuracy if it does not disturb cell
attachment42. Tips should also be changed if necessary to
reduce cross contamination. In general, references can be
found in technical support materials for particular handling
system. A standard operating procedure (SOP) for liquid
handling was recommended by Taylor et al.43. Smart appara-
tuses, such as the FLIPR system, have already added those
special settings to their associated software.
3.5. Other factors
Optimization ought to include assay volume, cell number,
reagent concentration, interval time, etc. Assay volume is
partially decided by the plate density: 100–200 mL/well for a
96-well plate, 30–100 mL/well for a 384-well plate and 2.5–
10 mL/well for a 1,536-well plate37. Cell number in each well
varies among different cell types and may start at 10,000 per
well in a 384-well format38. To obtain high signal with low
cost, concentrations of reagents such as buffer, substrate and
testing compound, etc. need to be adjusted as well. Usually,
compounds are stored in DMSO which is toxic for living cells.
Hence, compound concentration should not pose signiﬁcant
cytotoxicity in terms of DMSO tolerance44, while reserving
sufﬁcient potency to achieve bioactivities. A smooth work ﬂow
and an appropriate time interval for each step are equally vital
to an efﬁcient HTS campaign.
Pilot assay will follow with positive and negative controls to
determine Z’ factor using the equation described previously45.
A Z’ factor in the range between 0.5 and 1 indicates that the
assay is suitable to HTS. For Z’ factors between 0 and 0.5, the
assay is still acceptable, however, re-optimization is strongly
recommended before large-scale application. If the Z’ factor is
less than 0, re-optimization must be carried out while the best
choice may be to completely re-design the assay.
Although the Z’ factor is a valuable indicator of assay
quality, naive use can be misleading, especially if the value is
around or less than 0.5. To exclude potential errors, the
concept of power, which reﬂects the probability of ﬁnding a
hit, was introduced46. Statistical analysis shows, for assays
with Z’ factor under 0.5, reduction of coefﬁcient of variation
(CV) is effective in elevating the power; in the case of constant
CV (40.15), a rise in signal to background ratio is important
for increased power46. It appears that cell proliferation may
signiﬁcantly affect the CV while incubation time exerts a
strong impact on signal to background ratio. Therefore, re-
optimization should be adopted accordingly in each case with
the concept of power in mind.4. Compound management
Assays with reasonable Z’ factors can be applied to large-scale
HTS. However, before the start of a screening campaign, there
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compounds need to be screened, which portion of the library
should be covered and what kind of HTS strategies ought to
be taken.4.1. Compound selection
Generally speaking, the more compounds screened, the more
hits that will be found. However, the budget for HTS is always
limited and the cost for screening the whole collection, which
may involve millions of compounds, is extremely high and the
associated hit rate may be unacceptable. Academic labora-
tories are recommended to start with screening small collec-
tions of biologically active molecules. Several pragmatic
strategies, which are guided by historical bioactivity data,
have been adopted for library design with positive results47.
Other than ﬁnancial considerations, one of the other concerns
for compound selection is the undesirable characteristics of
sample structures. Some compounds in HTS libraries are too
complex to reach protein targets in cells48, while others that
were frequently deﬁned as hits in primary screening turned out
to be artifacts in later validation due to undesirable structure
features49.
For rational compound selection, there are some tips that
can be followed. Compounds should be soluble in the medium
of choice, physically stable50 and neither interfere with the
assay nor chemically modify proteins. When interacting with
cells, they should also be permeable, non-toxic, non-mutagenic,
and bioavailable. Commonly, undesirable compounds can be
excluded through computer-assisted physicochemical and func-
tional group ﬁlters. The ﬁlters, ﬁrst introduced by Lipinski,
include molecular weight, calculated log P, number of hydro-
gen-bond donors and acceptors, rotatable bonds, polar surface
area and charge state51–53. All of them are aiming to exclude
‘non-drug like’ compounds with potentially low oral bioavail-
ability and solubility in bioassays. Application of these ‘drug-
gable’ ﬁlters may yield libraries with relatively low hit rates.
However, the quality of the hits will be markedly improved.
Compounds after this passage can be considered as candi-
dates for screening. Inspection of structures prior to HTS is
still advisable because some of them are sufﬁciently similar or
of little novelty. Due to the fact that the ultimate goal for HTS
is to discover new chemical entities with therapeutic relevance,
compound libraries with great structural diversity are usually
preferable54. Clustering is used to select representatives from
screening libraries55. There are two competing demands that
are difﬁcult to reconcile. Before screening, we normally wish
to cover as much of chemical space as possible, while noting
that any given representative may not actually represent all the
molecules in its class56. Clustering makes sense for expanding
on hits once found, but its merit relative to the selection of a
library member remains controversial as it is hard to conﬁrm
the validity.
Natural products and synthetic compounds inspired by
them continue to attract considerable attention as a strategy
to augment screening libraries57,58. Natural products often
possess sound pharmacokinetic proﬁles, and nearly one half of
the currently approved drugs are either mimicries or derived
from them59. Moreover, a natural product that inﬂuences a
discrete molecular event within a cell may not directly bind the
target, and protein behavior (e.g., aggregation) is often subjectto the inﬂuence of signaling pathways60,61, which can create
opportunities for therapeutic modulation and determination
of pathological mechanisms. Many natural products are vastly
different from synthetic compounds in structures62. For these
reasons, we feel it prudent to deploy libraries that include
natural products.
It is worth pointing out that screening an already established
chemical space offers many advantages. These compounds are
generally known to be biologically active, which increases the
successful rate of drug discovery. Many small companies have
now been started based on rescreening known compounds to
develop drugs for novel indications. Normally, compounds in
HTS libraries are dissolved in 96-well microplates. Cherry
picking compounds from such plates to establish optimal
library for particular screenings is extremely time consuming
albeit possible. A simple solution is to focus on plate-based
diversity rather than single compound-based diversity63.4.2. Pooling strategy
Pooling in HTS refers to the act of testing mixtures of
compounds in primary screening. Because most compound
libraries contain only a small portion of active compounds,
pooling can signiﬁcantly reduce the number of tests as oppose
to the single compound per well approach. On the other hand,
pooling is also controversial due to concerns surrounding
potential molecular interactions in mixtures and chaos in
signaling pathways induced by multiple molecules. Nonethe-
less, historical successes imply that pooling is still a practical
and necessary part of HTS64.
Pooling schemes can be roughly divided into two categories:
adaptive and non-adaptive. For adaptive pooling65,66, a ﬁxed
number of compound plates are combined into one plate for
primary screening and each compound is screened for only
one time. Compounds in positive wells are re-screened indivi-
dually to identify the active hit(s). For example, a library with
100-compound plates could be pooled into 10 plates: each well
contains 10 compounds. These 10 plates are screened and the
10 compounds in each positive well are re-screened individu-
ally. The adaptive pooling method is very efﬁcient with a
10-fold increase in throughput. However, the false negative
rate is high such that active compounds are easily missed as a
result of system error. Moreover, results are delayed due to
two-stage primary screening. In contrast, non-adaptive scheme
involves the test of all pooled compounds in a single run.
Typically each compound was assessed multiple times67,68
depending on how many repeats are desired. For example,
orthogonal pooling allows each compound to appear twice in
the primary screening. During HTS implementation, the 100-
compound plates are arranged as a 10 10 matrix, 10 different
plates in the same row are combined into one plate, resulting
in 10 row plates (called X-plate). In the same way, 10 different
plates in the same column are pooled into another plate,
leading to 10 column plates (called Y-plate). Thus, the entire
library is reduced to 20 plates, each well contains 10 com-
pounds, and all the compounds will appear twice in HTS, once
in X-plate and the other in Y-plate. Some complex non-
adaptive pooling strategies allow compounds to repeat more
than twice, however, these are beyond our discussion here. In
orthogonal pooling, each active compound is required to show
activity in both wells of X- and Y-plate in order to be classiﬁed
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does conserve both resources and time by conducting a
reasonably efﬁcient screening in a single run. Although false
positives occur when an inactive compound is tested with
different active compounds in both X- and Y-plate, such error
tends to be rare, especially when the fraction of active
compounds in library is small.
To prevent interactions among compounds during pooling,
there are certainly some principles to remember. First, the
fewer the compounds pooled the less the multiple interactions
will appear. Second, pooling dissimilar compounds can reduce
interactions. Finally, it would be better to systematically
prevent speciﬁc chemical classes such as electrophiles and
nucleophiles from being mixed. Computational methods have
been developed to design adaptive pooling, which use struc-
ture information to optimize pools for maximal coverage of
chemical spaces, while minimizing overlaps69. Because of
repeats and one stage screening, non-adaptive pooling is more
common in HTS. A simulation-based approach has been
proposed to exploit the ability of non-adaptive pooling and
to design better pooling strategies and decoding techniques70.5. Data analysis
Analyses of data generated by HTS are always challenging
due to the amount of information and the complexity of
statistics40. A 3-step statistical decision methodology is thus
recommended by Shun et al.71. Step 1 is to determine the most
appropriate data processing method and to establish criteria
for quality control and hit identiﬁcation. Step 2 is to perform a
multilevel statistical and graphical review of the data to
exclude those that failed to meet the standard. Step 3 is to
apply the established criterion to the quality-assured data in
order to identify active compounds. HTS data usually show
some sort of distortion as a result of systematic errors. To
correct and remove outliers, stringent quality control measures
are required. Furthermore, hit identiﬁcation is more than just
ﬁnding highly active compounds, exclusion of false positive/
negative samples should also be a priority during the selection.
5.1. Systemic errors
Many technical, procedural or environmental factors can
cause systemic measurement errors. Without correction, such
deviation can signiﬁcantly curtail hit selection and hence,
should be identiﬁed as quickly as possible72,73. Among which,
spatial system error deﬁned as differences between wells due to
asymmetrical location is seen most frequently. It could result
from a discriminating process operated by liquid handling or
detection devices. For instance, in a poorly calibrated appa-
ratus, data obtained from one side of the plate may differ
drastically from that seen on the other side. Under most
circumstances, such system errors are measurable, predict-
able74 and correctable by applying statistical means like the
median ﬁlter approach75,76. The other systemic error com-
monly encountered relates to the edge (or side) effect. Wells
located on the edge of the plate always give incorrect results
because of physical or environmental variances (e.g., evapora-
tion). Normalization is thus crucial, particularly when positive
and negative controls are arranged on the side of the plate.
Statistical tools have been developed to estimate and correctthis type of errors75,77, and experimental studies suggest that
incubating newly seeded plates at room temperature before
placing them in a 37 1C CO2 chamber could signiﬁcantly
reduce the edge effect78. An alternative method to avoid
systemic errors is the use of whole sample area based data
analysis instead of control based analysis to achieve both
efﬁciency and accuracy79.5.2. False positive and false negative
In statistics, basically, there are two types (I and II) of errors
that can be made when making interpretations. Type I error,
also known as false positive, deﬁnes a wrong decision that is
made when a test rejects a true null hypothesis, while type II
error, or false negative, stands for a wrong decision made
when a test fails to reject a false null hypothesis. In the case of
HTS, false positive represents compounds which are identiﬁed
as hits by statistical analysis but are not truly active; false
negative is the mistake of failing to identify true active
compounds as hits through statistical process. Repeats or
follow-up studies, either in the same setting or through
different assays, can always minimize such errors40,80. In the
real situation, however, compounds are usually screened only
once and repeats are not feasible in primary HTS. Pooling
strategy allows each compound to be tested at least twice,
thereby providing inherent repeats to reduce false positives.5.3. Hit identiﬁcation
Identiﬁcation of active compounds as hits is the most exciting
part of statistical process. Criteria or threshold for hit
selection are established, and normally, hits are identiﬁed as
samples that generate the highest measured activity, for
example, compounds shown the highest 1% activity or whose
responses exceed a ﬁxed ‘percent of control’ threshold40. The
latter actually determines the rate of false positive and false
negative hits. A low threshold increases the number of hits
identiﬁed and reduces the probability of false negatives,
but inevitably raises type I errors. On the other hand, high
threshold reduces false positives, but increases false negatives.
Proper threshold is set according to the nature of HTS
conducted. For tough targets which have proven to be difﬁcult
to ﬁnd small molecule modulators, any hits with demonstrable
activities should not be ignored. It follows that a lower
threshold might be applied and false positives would be
excluded at the validation stage. As far as well executed assays
are concerned, a higher threshold is advisable in order to save
labor in secondary screenings. There are times when HTS data
are extremely noisy, low threshold does not necessarily
improve the yield of hits but dramatically enhances the burden
of validation. Under such circumstances, naive Bayes classiﬁer
is recommended for rational selection of potential hits81.
Other than this, statistical tools such as compound set
enrichment can also help us to identify active chemical series
rather than just individual active compounds, which may
prove to be useful for follow-up studies82.
Although data analysis is essential, the focal point for a
successful HTS resides in the screening process per se. Appro-
priate statistical methods only ascertain the conclusion drawn
from the data set is empirically right and do not impact the
Zhiyun Zhang et al.436assay quality at all. They can also be employed during an HTS
campaign to quickly react to or avoid quality problems83.6. Lead validation
Hits selected from statistical analysis need to be validated with
repeats before making a conclusion. Assays used for validation
could be the same as primary screenings, while methods that
address the functionality of a compound are highly valuable in
this stage. Different from biochemical assays, functional assess-
ment is generally directed towards multiple targets, and an array
of cell-based models may be required to exclude off-target effects.
It is noted that conﬁrmed hits are sometimes scarcely available
and some of them display ambiguous activities in different assay
systems, rendering the validation extremely frustrating. There-
fore, the key is to capture as many potent hits as possible based
on the primary data, and one way to achieve this goal is cherry
picking additional compounds for validation in accordance with
the Bayes classiﬁer81.
Validation can exclude most false positive compounds.
Some false positives were so peculiar that they became
candidates, but ended up with failure after wasting a great
deal of time and resources. Studies have described the
structural classes and known mechanisms of such non-lead
like false positives84,85, and computational approach to
exclude such compounds is now available85. To increase the
success rate of drug discovery, ideal leads should possess both
structural novelty and drug-like properties, as proposed by
Lipinski’s ‘rule of 5’51.7. Conclusions
Cell-based HTS as a more physiological relevant assay system
has become increasingly popular in modern drug discovery.
To execute a high quality HTS, comprehensive coordination is
required throughout the screening process, including screening
strategy, target selection, cell line generation, signal detection,
statistical analysis, hit identiﬁcation and lead validation.
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